Spinraza denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Spinraza as Duplicate Therapy

Spinraza (nusinersen) is an intrathecal antisense oligonucleotide approved by the FDA for spinal muscular atrophy (SMA). A duplicate-therapy denial from Aetna typically occurs when another SMA-targeted treatment — such as Zolgensma (onasemnogene abeparvovec) or Evrysdi (risdiplam) — is already on file for the patient, and Aetna's policy does not cover concurrent use of multiple SMA disease-modifying therapies.

This denial is frequently appealed successfully, because the clinical landscape for SMA is evolving and the appropriateness of a particular agent depends on the patient's specific SMA type, age, mutation status, prior treatment history, and tolerability. Aetna's duplicate-therapy determination is a coverage-policy decision, not a clinical judgment about your patient.

## Federal Appeal Rights

• ACA §2719 external review: If the plan is non-grandfathered, an independent external review is available — typically within approximately four months of the denial. An IRO reviewer is not bound by Aetna's internal policy interpretation.
• ERISA §503 full-and-fair review: Employer-plan patients have the right to see the exact Aetna policy language used to deny coverage and to submit a rebuttal.
• Expedited review: SMA is a progressive, life-threatening condition. If delaying therapy poses serious risk, an expedited appeal must be processed on an urgent timeline.

## Documentation to Gather

• SMA diagnosis and genetic confirmation: Genetic testing results confirming the specific SMN1/SMN2 copy number and mutation type; neurologist diagnosis notes with ICD code.
• Prior therapy history: Complete record of any previous SMA disease-modifying therapy — dates, doses, responses, and reason for transition or inadequate response.
• Rationale for Spinraza specifically: A detailed letter from the treating neurologist or neuromuscular specialist explaining why Spinraza is the medically appropriate choice for this patient at this time, and why the prior or concurrent therapy does not adequately address the clinical need.
• Functional trajectory documentation: Serial assessments of motor function, respiratory status, and swallowing documented in the chart, showing the clinical stakes of treatment gaps.
• Published clinical guidance: Reference the applicable professional society guidance (e.g., from the relevant neuromuscular disease specialty organizations) on SMA treatment sequencing without citing specific statistics.

## Criteria-Mapping Framework

Request Aetna's current Clinical Policy Bulletin for Spinraza in writing. Identify each coverage requirement and address each one directly:

| Aetna Policy Requirement | Supporting Documentation | |---|---| | Confirmed SMA diagnosis with genetic documentation | Genetic report dated [date] | | Medical-necessity rationale distinguishing from prior therapy | Neurologist letter dated [date] | | [Other stated requirements] | [Chart citation] |

The letter from the treating specialist is the most powerful element in this appeal — it should directly address Aetna's duplicate-therapy logic and explain the clinical distinction.